TriSalus Life Sciences Reports 52% Revenue Growth in Q2 2025; Net Loss Increases to $9M, EPS at $0.27

Reuters08-13
<a href="https://laohu8.com/S/TLSI">TriSalus Life</a> Sciences Reports 52% Revenue Growth in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025; Net Loss Increases to $9M, EPS at $0.27

Trisalus Life Sciences Inc. (Nasdaq: TLSI) has reported its financial results for the second quarter ended June 30, 2025, showing a revenue of $11.2 million, which marks a 52% increase compared to the same period in 2024 and a 22% growth quarter-over-quarter. This revenue growth was primarily driven by enhanced selling resources and increased market share of the TriNav system. Despite this growth, the company experienced a net loss attributable to common stockholders of $9.0 million, up from a $5.1 million net loss in the same period of the previous year. The increase in net loss is primarily attributed to non-cash adjustments related to the fair value of a contingent earnout liability. The company has confirmed its revenue guidance, projecting at least 50% growth due to sustained commercial momentum. Additionally, Trisalus Life Sciences has simplified its capital structure through an exchange offering of Series A Preferred stock and is positioned with $26.5 million in cash and cash equivalents as of June 30, 2025, which is expected to support the company in reaching positive adjusted EBITDA by the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250812845625) on August 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment